Ankylosing Spondylitis: Affected Areas, Symptoms, and Systemic Manifestations

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the axial skeleton. It belongs to the spondyloarthritis (SpA) family and is strongly associated with HLA-B27 (90% of patients).

Primary Axial Involvement

  • Sacroiliac (SI) joints: Earliest and most consistent site (sacroiliitis)
  • Spine: Vertebral bodies (syndesmophytes → "bamboo spine"), discovertebral junctions (Romanus lesions), facet joints
  • Progressive fusion: Ankylosis → loss of spinal mobility, kyphosis

Peripheral Joint Involvement (30-50%)

  • Large joints: Hips (25-35%), shoulders, knees, ankles
  • Asymmetric oligoarthritis typical
  • Enthesitis: Inflammation at tendon/ligament insertion — Achilles, plantar fascia, costochondral junctions

Extra-Articular Manifestations

SystemManifestationFrequency
EyesAcute anterior uveitis (iritis)25-40% (recurrent, unilateral)
GIInflammatory bowel disease (Crohn's, UC)5-10% clinical; up to 60% subclinical
SkinPsoriasis10-15%
CardiacAortic regurgitation, conduction defects, cardiomyopathy<10%
PulmonaryApical fibrosis, restrictive lung diseaseVariable
RenalIgA nephropathy, amyloidosis (late)Rare
NeurologicCauda equina syndrome (late, from dural ectasia)Rare

Characteristic Symptom Pattern

  • Inflammatory back pain: Age <45 onset, >3 months duration, improves with exercise, worse with rest, night pain (awakens 2nd half), morning stiffness >30 min
  • Alternating buttock pain
  • Fatigue (inflammatory cytokine-driven)
  • Enthesitis pain: Heel (Achilles/plantar), chest wall

Diagnostic Criteria (ASAS)

  • Imaging arm: Sacroiliitis on imaging (X-ray: modified NY criteria; MRI: active inflammation) + ≥1 SpA feature
  • Clinical arm: HLA-B27+ + ≥2 SpA features (inflammatory back pain, arthritis, enthesitis, uveitis, dactylitis, psoriasis, Crohn's/UC, good NSAID response, family history)

Treatment Overview

  • NSAIDs: First-line; continuous > PRN for disease modification
  • Biologics: TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), IL-17 inhibitors (secukinumab, ixekizumab), JAK inhibitors (upadacitinib)
  • Physical therapy: Daily mobility, posture, breathing exercises — cornerstone
  • No DMARDs (methotrexate, sulfasalazine) for axial disease — only for peripheral arthritis
  • Surgery: Hip replacement, spinal osteotomy (severe fixed deformity)

Monitoring

  • BASDAI (disease activity), BASFI (function), BASMI (mobility)
  • CRP/ESR (correlate poorly with axial activity)
  • Imaging: MRI for inflammation; X-ray for structural damage (syndesmophytes)
  • Ophthalmology for uveitis screening
  • Cardiac/pulmonary eval if symptoms

Key message: AS is more than back pain—it's a systemic inflammatory disease. Early rheumatology referral, NSAID trial, and MRI sacroiliac joints if clinical suspicion high. Physical therapy is non-negotiable for long-term function.

Bones, Joints & Muscles - Related Articles